Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier

A subgroup of patients treated with infliximab lose response to the treatment and one reason for this is the development of anti-drug antibodies (ADA). If used optimally, measuring drug and ADA level could lead to a more personalized and efficient treatment regime, and enable identification of ADA-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharlamova, Nastya, Hermanrud, Christina, Dunn, Nicky, Ryner, Malin, Hambardzumyan, Karen, Vivar Pomiano, Nancy, Marits, Per, Gjertsson, Inger, Saevarsdottir, Saedis, Pullerits, Rille, Fogdell-Hahn, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385065/
https://www.ncbi.nlm.nih.gov/pubmed/32793189
http://dx.doi.org/10.3389/fimmu.2020.01365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385065/
https://www.ncbi.nlm.nih.gov/pubmed/32793189
http://dx.doi.org/10.3389/fimmu.2020.01365

Ejemplares similares